IPP Bureau
Thermo Fisher to set up manufacturing facility in Mebane N.C.
By IPP Bureau - November 13, 2021
The US $ 192.5 mn US government contract will help fund the centre of excellence to boost the domestic supply of critically needed laboratory plastics
Aster DM Healthcare PAT at Rs 107 cr. in Q2FY22
By IPP Bureau - November 13, 2021
Aster DM Healthcare announced its financial results for the quarter ended September 30, 2021
DawaDost rolls out diabetes medicine at Re 1 per day
By IPP Bureau - November 13, 2021
The start-up has announced the scheme to mark World Diabetes Day
Natco Pharma PAT at Rs 65.1 cr. in Q2FY22
By IPP Bureau - November 12, 2021
Natco Pharma has reported consolidated financial results for the period ended September 30, 2021
Meridian Bioscience receives U.S. FDA Emergency Use Authorization for Revogene SARS-CoV-2 molecular assay
By IPP Bureau - November 12, 2021
The company expects to begin shipping this product before the end of its fiscal first quarter, ending December 31, 2021
World’s first Whole Genome Sequencing study uncovers new and potential therapies
By IPP Bureau - November 12, 2021
The ground-breaking project, led by Genomics England and NHS England, was established in 2013 to sequence 100,000 whole genomes from NHS patients and their families
Ronapreve gets the green light from CHMP to treat non-hospitalised Covid-19 patients
By IPP Bureau - November 12, 2021
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
Jubilant Biosys expands Chemistry Innovation Research Centre
By IPP Bureau - November 12, 2021
The centre has an initial capacity of 500 FTEs
Sun Pharma to introduce molnupiravir in India
By IPP Bureau - November 12, 2021
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
Covaxin well tolerated with no safety concerns: Lancet
By IPP Bureau - November 12, 2021
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Solara Active Pharma Sciences PAT slides to Rs 29.71 cr in Q2FY22
By IPP Bureau - November 12, 2021
Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.
J.B Chemicals & Pharmaceuticals PAT at Rs 98 cr. in Q2FY22
By IPP Bureau - November 12, 2021
J. B. Chemicals & Pharmaceuticals Limited (JBCPL), announced its financial results for the second quarter ended 30th September, 2021
Alembic Pharma PAT at Rs 169.29 cr. in Q2FY22
By IPP Bureau - November 11, 2021
The Board of Directors of Alembic Pharmaceuticals have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021.
Metropolis Healthcare PAT at Rs 58.26 cr in Q2FY22
By IPP Bureau - November 11, 2021
Metropolis Healthcare has reported consolidated financial results for the period ended September 30, 2021
Curadev Pharma partners with CMC Vellore for dengue research
By IPP Bureau - November 11, 2021
The company will provide the technical and financial resources to support the study
